Targeted Therapies in Non-small Cell Lung Cancer: Present and Future

Overview

Journal Fac Rev

Specialty Biomedical Engineering

Date 2023 Sep 7

PMID 37675274

Authors

Jessica McLaughlin

Jonathan Berkman

Patrick Nana-Sinkam

Affiliations

Soon will be listed here.

Abstract

Lung cancer is the leading cause of malignancy-related death in the United States and the second most common cancer diagnosis worldwide. In the last two decades, lung cancer treatment has evolved to include advances in the development of mutation-based targeting, immunotherapy, radiation therapy, and minimally invasive surgical techniques. The discovery of lung cancer as a molecularly heterogeneous disease has driven investigation into the development of targeted therapies resulting in improved patient outcomes. Despite these advances, there remain opportunities, through further investigation of mechanisms of resistance, to develop novel therapeutics that better direct the personalization of lung cancer therapy. In this review, we highlight developments in the evolution of targeted therapies in non-small cell lung cancer, as well as future directions shaped by emerging patterns of resistance.

Citing Articles

Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy.

De Lucia A, Mazzotti L, Gaimari A, Zurlo M, Maltoni R, Cerchione C Front Immunol. 2025; 16:1515748.

PMID: 39995659 PMC: 11847692. DOI: 10.3389/fimmu.2025.1515748.

Machine Learning and Computed Tomography Radiomics to Predict Disease Progression to Upfront Pembrolizumab Monotherapy in Advanced Non-Small-Cell Lung Cancer: A Pilot Study.

Janzen I, Ho C, Melosky B, Ye Q, Li J, Wang G Cancers (Basel). 2025; 17(1.

PMID: 39796687 PMC: 11719007. DOI: 10.3390/cancers17010058.

Role of 4-Thiazolidinone-Pyrazoline/Indoline Hybrids Les-4369 and Les-3467 in BJ and A549 Cell Lines.

Kosinska K, Skora B, Holota S, Shepeta Y, Tabecka-Lonczynska A, Lesyk R Cells. 2024; 13(12.

PMID: 38920636 PMC: 11202306. DOI: 10.3390/cells13121007.

Bioinformatics analysis and validation of CSRNP1 as a key prognostic gene in non-small cell lung cancer.

Xu Z, Zhou H, Luo Y, Li N, Chen S Heliyon. 2024; 10(7):e28412.

PMID: 38560128 PMC: 10979096. DOI: 10.1016/j.heliyon.2024.e28412.

References

Melosky B, Wheatley-Price P, Juergens R, Sacher A, Leighl N, Tsao M . The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer. Lung Cancer. 2021; 160:136-151. DOI: 10.1016/j.lungcan.2021.06.002. View

Drilon A, Subbiah V, Gautschi O, Tomasini P, De Braud F, Solomon B . Selpercatinib in Patients With Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial. J Clin Oncol. 2022; 41(2):385-394. PMC: 9839260. DOI: 10.1200/JCO.22.00393. View

Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-57. DOI: 10.1056/NEJMoa0810699. View

Kazandjian D, Blumenthal G, Chen H, He K, Patel M, Justice R . FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements. Oncologist. 2014; 19(10):e5-11. PMC: 4201002. DOI: 10.1634/theoncologist.2014-0241. View

Shaw A, Bauer T, de Marinis F, Felip E, Goto Y, Liu G . First-Line Lorlatinib or Crizotinib in Advanced -Positive Lung Cancer. N Engl J Med. 2020; 383(21):2018-2029. DOI: 10.1056/NEJMoa2027187. View

Dudnik E, Bar J, Peled N, Bshara E, Kuznetsov T, Cohen A . Efficacy and Safety of BRAF Inhibitors With or Without MEK Inhibitors in BRAF-Mutant Advanced Non-Small-Cell Lung Cancer: Findings From a Real-Life Cohort. Clin Lung Cancer. 2019; 20(4):278-286.e1. DOI: 10.1016/j.cllc.2019.03.007. View

Recondo G, Bahcall M, Spurr L, Che J, Ricciuti B, Leonardi G . Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC. Clin Cancer Res. 2020; 26(11):2615-2625. DOI: 10.1158/1078-0432.CCR-19-3608. View

Okura N, Nishioka N, Yamada T, Taniguchi H, Tanimura K, Katayama Y . ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in -Mutated Non-Small Cell Lung Cancer. Clin Cancer Res. 2020; 26(9):2244-2256. DOI: 10.1158/1078-0432.CCR-19-2321. View

Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot A, Mezquita L . Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019; 30(8):1321-1328. PMC: 7389252. DOI: 10.1093/annonc/mdz167. View

10.

Passaro A, Peters S . Setting the Benchmark for -Mutated NSCLC. N Engl J Med. 2022; 387(2):180-183. DOI: 10.1056/NEJMe2207902. View

11.

Janne P, Baik C, Su W, Johnson M, Hayashi H, Nishio M . Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, -Mutated Non-Small Cell Lung Cancer. Cancer Discov. 2021; 12(1):74-89. PMC: 9401524. DOI: 10.1158/2159-8290.CD-21-0715. View

12.

Yun J, Lee S, Kim S, Jeong S, Kim J, Pyo K . Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of Exon 20 Insertion-Driven NSCLC. Cancer Discov. 2020; 10(8):1194-1209. DOI: 10.1158/2159-8290.CD-20-0116. View

13.

Sholl L, Aisner D, Varella-Garcia M, Berry L, Dias-Santagata D, Wistuba I . Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. J Thorac Oncol. 2015; 10(5):768-777. PMC: 4410843. DOI: 10.1097/JTO.0000000000000516. View

14.

Dziadziuszko R, Smit E, Dafni U, Wolf J, Wasag B, Biernat W . Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP). J Thorac Oncol. 2019; 14(6):1086-1094. DOI: 10.1016/j.jtho.2019.02.017. View

15.

Farago A, Taylor M, Doebele R, Zhu V, Kummar S, Spira A . Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an Gene Fusion. JCO Precis Oncol. 2018; 2018. PMC: 6132056. DOI: 10.1200/PO.18.00037. View

16.

Kim D, Mehra R, Tan D, Felip E, Chow L, Camidge D . Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol. 2016; 17(4):452-463. PMC: 5063047. DOI: 10.1016/S1470-2045(15)00614-2. View

17.

Dziadziuszko R, Krebs M, De Braud F, Siena S, Drilon A, Doebele R . Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic Fusion-Positive Non-Small-Cell Lung Cancer. J Clin Oncol. 2021; 39(11):1253-1263. PMC: 8078299. DOI: 10.1200/JCO.20.03025. View

18.

Gatalica Z, Xiu J, Swensen J, Vranic S . Molecular characterization of cancers with NTRK gene fusions. Mod Pathol. 2018; 32(1):147-153. DOI: 10.1038/s41379-018-0118-3. View

19.

Shaw A, Ou S, Bang Y, Camidge D, Solomon B, Salgia R . Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014; 371(21):1963-71. PMC: 4264527. DOI: 10.1056/NEJMoa1406766. View

20.

Riely G, Neal J, Camidge D, Spira A, Piotrowska Z, Costa D . Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with Exon 20 Insertion Mutations from a Phase I/II Trial. Cancer Discov. 2021; 11(7):1688-1699. PMC: 8295177. DOI: 10.1158/2159-8290.CD-20-1598. View